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Original Article
Ulinastatin did not reduce mortality in elderly multiple
organ failure patients: a retrospective observational study
in a single center ICU
Masatoshi Uchida,1,2 Toshikazu Abe,2,3 Kazuyuki Ono,1 and Nanako Tamiya2
1Department of Emergency and Critical Care Medicine, Dokkyo Medical University, Tochigi, 2Department of Health
Services Research, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, and 3Department of Emergency
and Disaster Medicine Juntendo University, Urayasu Hospital, Urayasu, Chiba, Japan
Aim: Our aim was to evaluate the effect of ulinastatin on 28-day mortality in patients who developed multiple organ failure (MOF)
related to their acute illness and were admitted to the intensive care unit (ICU).
Methods: We carried out a retrospective observational study of MOF patients in a general ICU of a tertiary care hospital in Japan
from January 2009 to December 2012. The primary outcome was 28-day all-cause mortality. Secondary outcomes were ventilator-free
days, ICU-free days, and vasopressor-free days at day 28. We investigated the association between ulinastatin treatment and out-
comes using multivariable regression analysis.
Results: A total of 212 MOF patients were included, 79 (37%) of whom received ulinastatin. The median age was 70 years (interquar-
tile range, 60–77) and median APACHE II score was 25 (interquartile range, 19–29). Overall 28-day mortality was 20%. There were no
significant differences between the ulinastatin group and the control group in age, gender, or APACHE II score. The ulinastatin group
had higher prevalence of sepsis (44% versus 22%, P = 0.001). Multivariable logistic regression analysis showed that ulinastatin was not
associated with 28-day mortality (odds ratio = 1.22; 95% confidence interval, 0.54–2.79). Moreover, ulinastatin did not reduce the
mortality in patients with sepsis (odds ratio = 1.92; 95% confidence interval, 0.52–7.13). However, ICU-free days and ventilator-free
days was significantly fewer in the ulinastatin group than control group.
Conclusions: In this retrospective observational study, ulinastatin was not associated with mortality in elderly patients with estab-
lished MOF, although it might be related to patient’s utility.
Key words: Multiple organ dysfunction syndrome, multiple organ failure, sepsis, systemic inflammation response syndrome,
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BACKGROUND
MULTIPLE ORGAN FAILURE (MOF) is a syndromein which two or more organs cannot be maintained
without intervention.1 Previous studies suggested that unbri-
dled systemic inﬂammatory response resulting from sys-
temic cytokine release leads to systemic inﬂammatory
response syndrome (SIRS) and MOF.1 It usually results
from infection, injury, shock, and hypermetabolism.2 Even
when the causes are different, SIRS manifests a similar
clinical picture and is regulated by common pro-inﬂamma-
tory cytokines, such as tumor necrosis factor-a, interleukin
(IL)-1, and IL-6.2 Excessive secretion and systemic distribu-
tion of these cytokines leads to systemic activation of neu-
trophils and monocytes.2 Activated neutrophils release
lysosomal enzymes including serine proteases and reactive
oxidant intermediates, and these cellular products induce tis-
sue damage and microcirculation injuries.2 Unbridled sys-
temic inﬂammation leads to tissue injury and injured tissue
becomes the new stimulus to recycle the inﬂammation pro-
cess, even if appropriate therapy for the initial insult has
been given.2 To break this vicious circle of inﬂammation,
many inﬂammation-directed therapies have been studied.
However, most of them have failed to show survival bene-
ﬁt.2 As a result, the mortality of MOF remains high.2
Ulinastatin is one a serine protease inhibitor in the multi-
functional Kunitz family found in human blood and urine.3
Basic research showed that ulinastatin had anti-
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inﬂammatory activity through suppressing neutrophil accu-
mulation and activation and inhibiting secretion of inﬂam-
matory cytokines.3 Clinical studies also reported that anti-
inﬂammatory activity of ulinastatin decreased the mortality
of SIRS conditions, such as sepsis4,5 and acute respiratory
distress syndrome.6 Thus, ulinastatin would be considered a
therapeutic approach for MOF. However, these clinical stud-
ies were mainly carried out in speciﬁc countries such as
China and India. It is pointed out that the health care system
in India is different from developed countries.7 In addition,
little is known about ulinastatin’s effects on most critically
ill patients, such as those with MOF. Therefore, it is difﬁcult
to adopt these results for critically ill patients in ICUs in
developed countries. Our aim was to evaluate the effect of
ulinastatin on clinical outcomes among patients with MOF.
METHODS
Ethics
THE STUDY PROTOCOL was reviewed and approvedby the ethics committee of Dokkyo Medical University
(Mibu, Japan). Patient consent was not required as data were
collected retrospectively.
Study design and participants
We undertook a retrospective observational study in a 10-
bed general intensive care unit (ICU) of a tertiary care hospi-
tal in Japan from January 2009 to December 2012. Patients
who were diagnosed with MOF within 24 h from ICU
admission were eligible for the study. The deﬁnition of
MOF referred to criteria in a previous study, which included
patients with MOF caused by various diseases.8 Further
details of deﬁnitions are as follows. Multiple organ failure
was deﬁned as the presence of two or more organ failures
related to their acute illness. Organ failures were deﬁned as:
(i) respiratory failure, mechanically ventilated and a PaO2/
FiO2 ratio of <300; (ii) hypoperfusion, to maintain circula-
tion, vasopressor agents (norepinephrine, epinephrine, vaso-
pressin, or >5 lg/kg/min dopamine) required for 2 h or
longer; (iii) renal dysfunction, in patients without known
chronic kidney disease, serum creatinine >1.93 mg/dL, or a
urine output of <500 mL/last 24 h (or 80 mL/last 4 h if a
24-h period of observation not available), in patients with
acute on chronic renal failure (predialysis), an absolute
increase of >0.90 mg/dL from baseline creatinine, or a urine
output of <500 mL/last 24 h (or 80 mL/last 4 h); and (iv)
thrombocytopenia, platelet count of ≤50 9 109/L.8 We
excluded patients who met any of these criteria: (i) younger
than 18 years; (ii) admitted after elective cardiac surgery;
(iii) died within 24 h of ICU admission; (iv) a history of
organ transplantation; (v) readmission to ICU within
28 days; (vi) treated with ulinastatin before ICU admission;
and (vii) treated within ulinastatin <3 days.
Data abstraction
Medical records were reviewed and data obtained by study
investigators. Baseline characteristics (age, gender, and
admission category), disease category, patient comorbidities,
baseline Sequential Organ Failure Assessment (SOFA) score
derived from values on ICU admission and Acute Physiol-
ogy and Chronic Health Evaluation Survey (APACHE) II
score derived from the worst values from the ﬁrst 24 h in
the ICU, number of failed organs, and therapeutic interven-
tions (ulinastatin, antibiotics, corticosteroid, vasopressor,
mechanical ventilation, renal replacement therapy [RRT],
intra-aortic balloon pumping, venoarterial extracorporeal
membranous oxygenation [VA-ECMO], and operation)
were recorded. The exposure was i.v. administration of uli-
nastatin (Miracrid; Mochida Pharmaceutical, Tokyo, Japan)
during their ICU stay. Ulinastatin exposure was deﬁned as
documented administration of ulinastatin at 300,000 IU/day
for 3 or more days. This dosage was approved for patients
with shock in Japan. The treatment duration was 3 or more
days. It based on previous randomized controlled trials
(RCTs).4–6,9–13 All clinical decisions, including ulinastatin
administration, were at the treating physician’s discretion.
Outcome measurements
The primary outcome was 28-day all-cause mortality. The
secondary outcomes included ventilator-free days (VFDs),
ICU-free days (ICUFDs), and vasopressor-free days
(VASFDs) at day 28. Patients who died prior to day 28 were
allocated 0 for VFDs, ICUFDs, and VASFDs.
Statistical analysis
Dichotomous variables were reported as counts and percent-
age, and comparisons between the two groups were carried
out with Pearson’s v2-test or Fisher’s exact test, as appropri-
ate. Continuous data were reported as mean and standard
deviation or median and interquartile range (IQR), and com-
pared using Student’s t-test or the Mann–Whitney U-test, as
appropriate. All statistical tests were two-tailed and P-values
<0.05 were considered statistically signiﬁcant. To assess the
association between ulinastatin and outcomes, we carried out
multivariable logistic regressions. We used ordinal logistic
regression models for VFDs, ICUFDs, and VASFDs. We
carefully selected covariates if the variable had statistically
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signiﬁcant differences between the ulinastatin and control
groups in univariate analysis or if it was clinically important.
Sepsis among disease category, corticosteroid use, vasopres-
sor use, RRT, and VA-ECMO among interventions were
selected for adjusted covariates because there were statistical
differences between two groups. The APACHE II score was
selected for adjusted covariates because of its clinical impor-
tance. We then undertook three analytical models: crude,
adjusting the APACHE II score, and adjusting factors of their
severity and treatment. In the ﬁnal model, adjusting factors
were sepsis, corticosteroid use, vasopressor use, RRT, VA-
ECMO, and APACHE II score. Then, we stratiﬁed patients
with sepsis as a secondary analysis. We did not select respira-
tory disease among disease category for adjusted covariate,
because none were given ulinastatin in respiratory disease
patients. All analyses were carried out with R version 3.1.1
(R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
DURING THE 48-month study period, 499 patientswere diagnosed with MOF within 24 h of ICU admis-
sion. Of these, 287 met exclusion criteria. Therefore, 212
patients were included in this analysis. Overall, 79/212
(37.2%) patients received ulinastatin (Fig. 1). At baseline,
the median age was 70 years (IQR, 60–77), 146/212 (69%)
were men, and the median APACHE II score was 25 (IQR,
19–29). Of 212 patients, 135 (64%) were aged 65 years and
older, 206 (97%) received mechanical ventilation, and 205
(97%) were on vasopressors. Baseline characteristics and
therapeutic interventions between the ulinastatin group and
the control group are shown in Table 1. There were no sig-
niﬁcant differences between the two groups in age, gender,
APACHE II score, or SOFA score. The ulinastatin group
had a higher prevalence of sepsis (35/79 [44%] versus 29/
133 [22%], P = 0.001), and they were more likely to receive
corticosteroids (37/79 [47%] versus 41/133 [31%],
P = 0.027), vasopressors (79/79 [100%] versus 126/133
[95%], P = 0.048), RRT (43/79 [54%] versus 49/133
[37%], P = 0.015), and VA-ECMO (18/79 [23%] versus 8/
133 [6.0%], P = 0.001). The overall 28-day mortality was
20.3% (43/212). Univariate analyses of patient outcomes are
shown in Table 2. In terms of 28-day mortality, there was
no signiﬁcant difference between the ulinastatin group and
the control group (20/79 [25%] versus 23/133 [20%],
P = 0.163). The VFDs, ICUFDs, and VASFDs were signiﬁ-
cantly fewer in the ulinastatin group. In logistic regression
after adjusting for APACHE II scores, there was also no sig-
niﬁcant difference in mortality (odds ratio [OR] = 1.59;
95% conﬁdence interval [CI], 0.79–3.21). The result was
similar in the ﬁnal model (OR = 1.22; 95% CI, 0.54–2.79)
(Table 3). Moreover, ulinastatin did not reduce the mortality
in patients with sepsis (OR = 1.92; 95% CI, 0.52–7.13).
After multivariable adjustment, ICUFDs and VFDs
Fig. 1. Study flow diagram of the effect of ulinastatin on mortality in elderly patients with multiple organ failure.
© 2017 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of
Japanese Association for Acute Medicine
92 M. Uchida et al. Acute Medicine & Surgery 2018; 5: 90–97
Table 1. Baseline characteristics of patients with multiple organ failure and ulinastatin treatment
Characteristics Ulinastatin group (n = 79) Control group (n = 133) P-value
Age, years, median (range)† 69.00 (20.00, 86.00) 70.00 (18.00, 88.00) 0.255
Age >65 years, n (%) 48 (60.8) 87 (65.4) 0.555
Male sex, n (%) 51 (64.6) 95 (71.4) 0.296
APACHE II score, median (IQR)† 25.00 (20.00, 30.00) 24.00 (19.00, 29.00) 0.370
SOFA score, median (IQR)† 9.00 (7.00, 11.00) 9.00 (7.00, 11.00) 0.886
Admission category, n (%)
Medical 56 (70.9) 92 (69.2) 0.792
Elective surgery 1 (1.3) 2 (1.5) 1.000
Emergency surgery 22 (27.8) 39 (29.3) 0.819
Pre-existing condition, n (%)
Liver cirrhosis 2 (2.5) 4 (3.0) 1.000
Congestive heart failure 2 (2.5) 0 (0.0) 0.138
Chronic dialysis 7 (8.9) 13 (9.8) 0.826
Immunodeficiency 4 (5.1) 16 (12.0) 0.093
Disease category, n (%)
Cardiovascular or vascular disorder 36 (45.6) 71 (53.4) 0.271
Respiratory disorder 0 (0.0) 16 (12.0) 0.001
Gastrointestinal disorder 4 (5.1) 5 (3.8) 0.730
Neurologic disorder 0 (0.0) 3 (2.3) 0.295
Sepsis 35 (44.3) 29 (21.8) <0.001
Trauma 2 (2.5) 0 (0.0) 0.138
Metabolic disorder 0 (0.0) 1 (0.8) 1.000
Hematologic disorder 0 (0.0) 1 (0.8) 1.000
Renal disorder 0 (0.0) 3 (2.3) 0.295
Other 2 (2.5) 4 (3.0) 1.000
Post cardiac arrest, n (%) 14 (17.7) 16 (12.0) 0.250
Organ failure, n (%)
Respiratory failure 74 (93.7) 121 (91.0) 0.485
Hypoperfusion 72 (91.1) 120 (90.2) 0.826
Renal dysfunction 35 (44.3) 48 (36.1) 0.236
Thrombocytopenia 22 (27.8) 28 (21.1) 0.260
No. of failed organs, n (%)
2 43 (54.4) 89 (66.9) 0.070
3 27 (34.2) 34 (25.6) 0.180
4 9 (11.4) 10 (7.5) 0.340
Interventions, n (%)
Antibiotics 79 (100.0) 129 (97.0) 0.120
Corticosteroid 37 (46.8) 41 (30.8) 0.019
Vasopressor 79 (100.0) 126 (94.7) 0.038
Mechanical ventilation 79 (100.0) 127 (95.5) 0.086
Renal replacement therapy 43 (54.4) 49 (36.8) 0.012
IABP 27 (34.2) 33 (24.8) 0.143
VA-ECMO 18 (22.8) 8 (6.0) <0.001
Operation 36 (45.6) 48 (36.1) 0.172
†Mann–Whitney U-test.
APAHCE II, acute physiology and chronic health evaluation II; IABP, intra-aortic balloon pumping; IQR, interquartile range; SOFA, sequential
organ failure assessment; VA-ECMO, venoarterial extracorporeal membranous oxygenation.
© 2017 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of
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remained signiﬁcantly fewer in the ulinastatin group
(Table 3). Although VASFDs did not show a signiﬁcant dif-
ference in the ﬁnal model, there was a trend toward fewer in
the ulinastatin group.
DISCUSSION
Key findings
IN THIS RETROSPECTIVE observational cohort study,we evaluated the association between ulinastatin and clin-
ical outcomes in severely ill established MOF patients. We
found that ulinastatin was not associated with 28-day mor-
tality. This ﬁnding did not change in the subgroup analysis
of sepsis patients. The VFDs, ICUFDs, and VASFDs in the
ulinastatin group were fewer than in the control group. In
this study, treatment with ulinastatin was not based on a
speciﬁc criteria. Although ulinastatin is approved for shock
due to trauma, infection, burn, hemorrhage, acute hypoper-
fusion, and pancreatitis in Japan, there is no robust indica-
tion for critically ill patients. Consequently, treatment with
ulinastatin was based on the treating physician’s discretion
in the studied institution. As a result, there were some differ-
ences between the ulinastatin and control groups. There
were no statistically signiﬁcant differences in severity score,
but patients in the ulinastatin group were more likely to
receive invasive organ support therapies, such as RRT and
VA-ECMO, than patients in the control group. Similarly,
corticosteroid and vasopressor were more used more often
in the ulinastatin group. Generally, corticosteroid was used
for refractory septic shock patients. Furthermore, the ulinas-
tatin group had a higher prevalence of sepsis. These ﬁndings
suggested that physicians tend to prescribe ulinastatin for
more severe patients, such as those with more severe organ
failure or refractory septic shock. However, the results were
not changed after adjustment for these imbalances among
severity, therapeutic interventions, and disease category.
That being said, the effects of ulinastatin might have been
underestimated, because there was no signiﬁcant difference
in mortality between the two groups, even though patients in
the ulinastatin group had more severe health conditions.
Relationship to previous studies
The anti-inﬂammatory activities, organ protective effect, and
clinical effectiveness of ulinastatin in several SIRS condi-
tions have been investigated in many animal studies14–16
and clinical studies.5,10,13,17–19 Based on these results, we
hypothesized that ulinastatin would have beneﬁcial effects
on MOF patients. However, ulinastatin treatment was not
associated with a favorable outcome in our study. There
were some reasons. First, even though ulinastatin affects the
plasma concentration of cytokines and inﬂammatory media-
tors, it may not affect mortality. Wu et al.11 undertook an
Table 2. Outcomes in patients with multiple organ failure
and ulinastatin treatment
Ulinastatin
group
(n = 79)
Control
group
(n = 133)
P-value
Death at 28 days, n (%)† 20 (25.3) 23 (17.3) 0.163
ICU-free days‡
Median 12 19 <0.001
Interquartile range 0–18.5 10–22
Vasopressor-free days‡
Median 16 21 0.009
Interquartile range 0–23 8–25
Ventilator-free days‡
Median 9 19 <0.001
Interquartile range 0–17 0–24
†v2-test.
‡Mann–Whitney U-test.
ICU, intensive care unit.
Table 3. Analyses of the relationship between ulinastatin
treatment and outcomes
Outcome OR 95% CI of OR P-value
Primary outcome: 28-day all-cause mortality†
Crude 1.62 0.82–3.19 0.162
Adjusted for
APACHE II score
1.59 0.79–3.21 0.195
Multivariable adjusted‡ 1.22 0.54–2.79 0.632
Secondary outcomes
ICU-free days§
Crude 0.31 0.19–0.52 <0.001
Multivariable adjusted‡ 0.44 0.25–0.75 0.003
Ventilator-free days§
Crude 0.42 0.25–0.69 <0.001
Multivariable adjusted‡ 0.49 0.28–0.84 0.010
Vasopressor-free days§
Crude 0.50 0.31–0.82 0.006
Multivariable adjusted‡ 0.66 0.38–1.15 0.143
†Logistic regression.
‡Adjusted for APACHE II score, sepsis, corticosteroid use, vaso-
pressor use, renal replacement therapy, and venoarterial extra-
corporeal membranous oxygenation.
§Ordinal logistic regression.
APACHE II, acute physiology and chronic health evaluation II; CI,
confidence interval; ICU, intensive care unit; OR, odds ratio.
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RCT of the effects of ulinastatin for patients with severe sep-
sis in China. There was no signiﬁcant difference in 28-day
mortality (control group, 18.2% versus ulinastatin group,
20.2%, P > 0.05) although ulinastatin signiﬁcantly reduced
inﬂammatory mediators in their study. Studies of patients
undergoing cardiac surgery with cardiopulmonary bypass
reported similar results in two meta-analyses.20,21 This dis-
crepancy between effects for inﬂammatory mediators and
clinical effectiveness was also observed in other anti-inﬂam-
matory therapy such as drotrecogin, activated protein C.22,23
Effects on inﬂammatory mediators may not be directly
linked to clinical beneﬁts in any situation. Second, ulinas-
tatin might reduce mortality in relatively young and mildly
ill patients. An RCT in severe sepsis patients5 showed that
the ulinastatin group had lower 28-day mortality (4/55
[7.3%] of ulinastatin group versus 12/59 [20.3%] of control
group, P = 0.045) and more VFDs (19.4  10.6 versus
10.2  12.5, P = 0.019). In that study, patients aged more
than 60 years and with a platelet count <30 9 109/L were
excluded. Consequently, included patients’ mean age was
37.1 years and mean APACHE II score was 13.4. Moreover,
74/119 (62.2%) patients had single organ failure. Another
RCT in SIRS patients in China10 observed that ulinastatin
treatment reduced mortality (1/30 [3.3%] in ulinastatin
group versus 6/30 [20%] in control group, P < 0.05) and the
occurrence rate of MODS (multiple organ dysfunction syn-
drome) (3/30 (10%) versus 11/30 (36.7%), respectively,
P < 0.05). In that study, patients’ mean age was 43 years.
In another RCT for pancreatitis patients in India,13 ulinas-
tatin treatment reduced mortality (1/35 (2.8%) in ulinastatin
group versus 6/32 (18.7%) in placebo group, P = 0.048) in
severe pancreatitis patients. In that study, patients aged more
than 70 years were excluded. As a result, the mean age of
severe pancreatitis was 42.2 years and the median APACHE
II score was 11 in the ulinastatin group (versus 13 in the
control group). In short, studies that have reported ulinas-
tatin’s favorable effects included relatively young and mild
ill patients compared to ours (median age, 70 years; median
APACHE II score, 25). Previous studies suggested that uli-
nastatin’s favorable effects for SIRS patients was caused by
its anti-inﬂammatory features (to decrease pro-inﬂammatory
mediators such as tumor necrosis factor-a and to increase
anti-inﬂammatory mediators such as IL-10).10,24,25 Mean-
while, it is said that the individual immune response is dif-
ferent between young and elderly patients.26 Among elderly
patients and those with numerous comorbidities, absent
hyper-inﬂammatory response is common and patients
rapidly develop the anti-inﬂammatory state.26 For these
patients, they might be already in an immunosuppressive
state when they develop MOF. This could explain why uli-
nastatin was not effective for our study cohort. Finally,
therapy with ulinastatin alone might not be effective. Several
studies9,24,25,27 reported survival beneﬁt from ulinastatin
combined with thymosin a1. Combination therapy might be
effective.
Significance and implications
To the best of our knowledge, this is the ﬁrst study to inves-
tigate the effects of ulinastatin treatment on established
MOF. As stated above, our cohort included the most
severely ill and elderly patients, compared with previous
studies. Our studied patients were very speciﬁc. However,
the number of elderly patients in the ICU are increasing and
their poor outcomes have been reported.28 We think it is
important to report that ulinastatin would not have signiﬁ-
cant effects for elderly and critically ill patients. Again, uli-
nastatin might have beneﬁcial effects for relatively young
and mildly ill patients, based on previous studies.5,10,13 Sev-
eral animal and human studies reported that ulinastatin could
have an organ-protective effect.15,29,30 Hence, ulinastatin
may work as “prevention” rather than “treatment” for organ
dysfunction. It would be important to detect the patients
who might develop organ dysfunction in the early phase of
disease and to give appropriate intervention.
Limitations
Our study has potential limitations. First, MOF is a well-
known clinical entity but there is no widely used deﬁnition.
For example, liver dysfunction and dysfunction of the central
nervous system were not included in the criteria of MOF we
used. Therefore, our results could not be adopted for patients
with MOF based on different criteria. Second, this study was
retrospective. Therefore, there were several differences
between the ulinastatin and control groups. As we stated
before, ulinastatin was administered for more severity ill
patients. This indication difference whether administrate uli-
nastatin or not might have led to selection bias. In particular,
signiﬁcant differences in secondary outcomes might have been
the result of this bias. We were aware of this bias based on
patients’ severity and disease category, but we adjusted it
using multivariable analysis. However, there might have been
uncontrolled confounders. Moreover, because of the nature of
the retrospective observational study design we cannot estab-
lish causality.
CONCLUSIONS
THIS RETROSPECTIVE STUDY suggested that ulinas-tatin treatment should not be associated with favorable
outcomes in elderly patients with established MOF.
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